Dexamethasone/netilmicin combination effective for inflammation after MIVS

Posted on

The combination dexamethasone/netilmicin (dexa/net) for the treatment of post-operative inflammation following sutureless micro-incision vitreoretinal surgery (MIVS) is safe and effective, according to a study.

In this multicenter, open, randomized clinical trial, patients were randomized to receive dexa/net (eyedrops solution and eye gel) or dexamethasone/tobramycin (eyedrops suspension and ointment) on the day of surgery and for the following 14 days 4 times daily. In the early post-operative phase, viscous formulations (gel or ointment) were used alone before starting a combination of eyes drop during the day and gel or ointment at night.

At the study end point, 92.9% of patients treated with dexa/net and 75.0% of patients treated with dexamethasone/tobramycin had a complete resolution of bulbar conjunctiva hyperaemia. No differences were observed between treatments for additional efficacy parameters, including palpebral conjunctival hyperemia, anterior chamber flare and cells, symptoms of ocular discomfort and ocular tolerance, adverse events, and intraocular pressure.

There were statistically significant differences for several subjective tolerance variables examined, including blurred vision, foreign body sensation, stickiness, burning, starting on postoperative day 1 when only the viscous formulations were used.

No increase in intraocular pressure or adverse events were found.


Rapisarda A, Arpa P, Fantaguzzi PM, et al. Dexamethasone/Netilmicin eye drops and eye gel for the treatment of ocular inflammation after micro-incisional vitreoretinal surgery. Clin Ophthalmol. 2020;14:3297-3303.

Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021